Rag D inhibitors belong to a class of small molecules that are designed to modulate the activity of the Rag D protein, which is a crucial component of the Rag GTPase family. The Rag GTPases play a pivotal role in regulating the mechanistic target of rapamycin complex 1 (mTORC1) pathway, a central signaling cascade in cellular growth and metabolism. Specifically, Rag D is one of the four GTPase subunits within the Rag complex, and its activation state dictates the nucleotide binding and interaction with other Rags. These interactions are vital in controlling mTORC1 activation in response to nutrient availability and cellular stress.
Rag D inhibitors function by targeting the activation or nucleotide-binding site of Rag D, thereby influencing the Rag complex's ability to transmit signals to mTORC1. These molecules are designed to interfere with the formation of active Rag complexes, preventing mTORC1 activation and subsequent downstream signaling events. This disruption can have profound effects on cellular processes, such as protein synthesis, autophagy, and nutrient sensing, making Rag D inhibitors valuable tools for investigating the intricate regulatory mechanisms governing cell growth and homeostasis.Researchers utilize Rag D inhibitors primarily in laboratory settings to gain insights into the molecular pathways that govern cellular responses to environmental cues. By manipulating the Rag D protein's activity, scientists can elucidate the role of mTORC1 signaling in various cellular processes and uncover novel targets for conditions related to dysregulated cell growth and metabolism.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $153.00 | 5 | |
Irreversibly binds to Bruton's tyrosine kinase (BTK), inhibiting B-cell receptor signaling, and disrupting the survival and proliferation of B-cells. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $116.00 $330.00 $510.00 $816.00 $1632.00 | 10 | |
Selectively inhibits B-cell lymphoma-2 (BCL-2) protein, promoting apoptosis in cancer cells by blocking the anti-apoptotic function of BCL-2. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Targets and inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase, blocking downstream signaling pathways in cancer cells. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Acts as a tyrosine kinase inhibitor, primarily targeting BCR-ABL, the abnormal fusion protein found in chronic myeloid leukemia (CML). | ||||||
Osimertinib | 1421373-65-0 | sc-507355 | 5 mg | $86.00 | ||
Specifically inhibits mutant forms of EGFR, which are common in non-small cell lung cancer (NSCLC), blocking tumor growth. | ||||||
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $206.00 $299.00 $485.00 | 10 | |
Inhibits poly (ADP-ribose) polymerase (PARP) enzymes, leading to DNA damage accumulation and cell death in BRCA-mutated cancer cells. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Targets multiple kinases, including BCR-ABL and Src family kinases, disrupting signaling pathways in leukemia and other cancers. | ||||||
CH5424802 | 1256580-46-7 | sc-364461 sc-364461A | 5 mg 50 mg | $191.00 $902.00 | ||
Selectively inhibits anaplastic lymphoma kinase (ALK), which is implicated in certain types of lung cancer, leading to tumor regression. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Inhibits multiple kinases, including RAF and VEGFR, blocking angiogenesis and cell proliferation in various cancers. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $128.00 $638.00 | 7 | |
Inhibits mTOR (mammalian target of rapamycin) signaling, reducing cell growth and proliferation in cancer and immunosuppression. | ||||||